NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
$20.14+0.85%
报价 2026-11-13
市值
$2.42B
EV
$2.96B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -51.4%
$18.89$41.45
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. | $2.42B | +0.9% | – | 99.7% | – | – | – | |
| RCUSArcus Biosciences, Inc. | $2.51B | -1.9% | -70.6% | 97% | – | – | – | |
| BEAMBeam Therapeutics Inc. | $2.36B | -5.0% | +6.9% | 100% | – | – | – | |
| PHVSPharvaris N.V. | $2.34B | -1.4% | – | 0% | – | – | – | |
| CLDXCelldex Therapeutics, Inc. | $2.26B | +1.1% | -51.9% | 100% | – | – | – | |
| PVLAPalvella Therapeutics, Inc. | $2.23B | -0.5% | – | 0% | – | – | – | |
| LKFTGalapagos N.V. Sponsored ADR | $2.23B | +0.1% | – | – | – | – | – | |
| IMNMImmunome, Inc. | $2.22B | +0.4% | -97.4% | -1,161.9% | – | – | – | |
| MRVIMaravai LifeSciences Holdings, Inc. | $2.14B | -1.8% | +16.0% | 34.6% | – | – | – | |
| 同行中位数 | – | – | -51.9% | 34.6% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。